[1] Clinical Pharmacology Group of Pediatrics Branch of Chinese Medical Association. Expert consensus on off-label medication in Chinese pediatrics[J]. Chinese Journal of Pediatrics(中华儿科杂志), 2016, 54(2): 101-103 [2] Zhang LL, Li YP, Liang Y, et al.Off-label drug use in hospitalized children: a systematic review[J]. Chin J Evid-based Med, 2012, 12(2): 176-187. [3] Dal Pan GJ, Monitoring the safety of medicines used off-label[J]. Clin Pharmacol Ther,2012,91(5): 787-795. [4] Yonas GT, Begashaw MG, Abebe BM, et al.Off label drug use in hospitalized children: a prospective observational study at Gondar University Referral Hospital, Northwestern Ethiopia[J]. Pharmacol Res Perspect , 2017 , 5(2): e00304. [5] Liu L,Yang HY,Lou Y,et al.Off-label prescriptions in intensive care unit: the Chinese experience[J]. Therapeutics and Clinical Risk Management , 2018(14):195-202. [6] Zhang LL, Li YP, Hu D, et al.Investigation on the out-of-specification drug use of pediatric inpatients in West China Sec-ond Hospital of Sichuan University in 2010[J]. Chinese Journal of Evidence-Based Medicine(中国循证医学杂志), 2012, 12(2): 161-167. [7] Liu JP, Xing JM.Evidence-based adverse drug reaction evaluation method[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2010, 17(1): 12-15 [8] Wu HZ, Dong ZJ.Investigation and analysis of out-of-specification medication in pediatric hospitalization[J]. Journal of Pediatric Pharmacy(儿科药学杂志), 2015, 21(2): 34-37. [9] Liu MY, Zhang SX, Song YQ.Analysis of off-label drug use in neonatology inpatients[J]. Chinese Pharmaceutical Affairs(中国药事), 2018, 32(3): 404-411. [10] Du L, Shang JG, Wang WJ, et al.Investigation on the current situation of out-of-label use of prescription drugs in pediatric outpatient and emergency departments in Suzhou[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2018, 38(3): 317-321. [11] Yan HY, Xu JB, Zhang WR, et al.Out-of-specification medication in pediatric inpatients[J]. Herald of Medical(医药导报), 2017, 36(7): 835-837. [12] Zhang M.Discussion on the appropriate dose of vitamin k1 for the treatment of neonatal hemorrhagic disease[J]. China Practical Medicine(中国实用医药), 2008 (20): 56. [13] Douglas L. Riegert J, Gerald W.et al.The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review[J]. Annals of Allergy, Asthma, & Immun- Ology,2002,89(4): 400-406. [14] Wang XY.Analysis of 17 cases of adverse drug reactions caused by intravenous infusion of vitamin K1 injection in children[J]. Pharmaceutical Research(药学研究), 2018, 37(9): 555-558. [15] Neonatal Surgery Group of Pediatric Surgery Branch of Chinese Medical Association. Chinese newborn nutrition support clinical application guidelines[J]. Chinese Journal of Pediatric Surgery, 2013, 34(10): 782-787. [16] Wang H, Li G, Liang H, et al.Participation of clinical pharmacists in the formulation and intervention of evaluation criteria for the rational application of pediatric parenteral nutrition[J]. Zhongnan Pharmaceutical, 2018, 16(10): 1458-1460. [17] Lin XY, Huang JP, Zhong HY.A study of fructose-1, 6-diphosphate in causing neonatal hypocacemia[J].Journal of Pediatric pharmacy,2009,15(1):16-17. [18] Ding SH, Lei ZB.Analysis of 80 cases of adverse reaction of fructose diphosphate[J].Chinese Journal of Pharmacoepidemiology,2012(5):240-242. [19] Shen KL, Deng L, Li YZ, et al.Expert consensus on the application of corticosteroid inhalation therapy in pediatrics[J]. The Journal of Clinical Pediatrics(临床儿科杂志), 2018, 36(2): 95-107. [20] Expert consensus on the application of nebulized inhalation therapy in respiratory diseases of the Chinese Medical Association Respiratory Diseases Committee. Expert consensus on the application of nebulized inhalation therapy in respiratory diseases[J]. Chinese Medical Journal(中华医学杂志), 2016,96(34): 2696-2708. [21] Eguale T, Buckeridge DL, Verma A.et al.Association of off-label drug use and adverse drug events in an adult population[J].JAMA Intern Med, 2016, 176(1): 55-63. [22] Saiyed MM, Lalwani T, Rana D.Is off-label use a risk factor for adverse drug reactions in pediatric patients? a prospective study in an Indian tertiary care hospital[J].Int J Risk Saf Med, 2015, 27(1): 45. [23] Zhou H, Li GH, Zhuo C, et al.Expert consensus on diagnosis, treatment, prevention and control of Stenotrophomonas maltophilia infection in China[J]. Chinese Medical Journal(中华医学杂志), 2013, 93(16): 1203-1213. [24] Kieran EA, Callaghan N, Donnell CP.Unlicensed and off label drug use in Irish neonatal intensive care unit:a prospective cohort study[J]. Acta Paediatr, 2014, 103(4): e139-142. [25] Ren XX.Risks and prevention of off-label medication[J]. Chinese Pediatric Emergency Medicine(中国小儿急救医学), 2018, 25(10): 4-7. [26] Drug Risk Management Group of Therapeutic Drug Monitoring and Research Professional Committee of Chinese Pharmacological Society. Expert consensus on off-label medication[J]. Adverse Drug Reactions Journal, 2015, 17(2): 101-103. [27] Guangdong Pharmaceutical Association.Expert Consensus on the Management of Drugs Over-drug Instructions in Medical Institutions[J]. Chinese Journal of Modern Applied Pharmacy(中国现代应用药学), 2017,34(3):436-438. [28] Shi Q, Wang XL, Wang W, et al.Analysis of off-label use of drugs in hospitalized neonates[J]. China Pharmacy(中国药房), 2014, 25(14): 1265-1267. |